These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15285706)

  • 21. Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors.
    Ko SY; Cheng C; Kong WP; Wang L; Kanekiyo M; Einfeld D; King CR; Gall JG; Nabel GJ
    J Virol; 2009 Jan; 83(2):748-56. PubMed ID: 18987146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dendritic cell targeted HIV-1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8
    Ngu LN; Nji NN; Ambada G; Ngoh AA; Njambe Priso GD; Tchadji JC; Lissom A; Magagoum SH; Sake CN; Tchouangueu TF; Chukwuma GO; Okoli AS; Sagnia B; Chukwuanukwu R; Tebit DM; Esimone CO; Waffo AB; Park CG; Überla K; Nchinda GW
    Immun Inflamm Dis; 2018 Mar; 6(1):163-175. PubMed ID: 29205929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mucosal and systemic anti-GAG immunity induced by neonatal immunization with HIV LAMP/gag DNA vaccine in mice.
    Goldoni AL; Maciel M; Rigato PO; Piubelli O; de Brito CA; Melo A; Marques ET; August JT; Duarte AJ; Sato MN
    Immunobiology; 2011 Apr; 216(4):505-12. PubMed ID: 20870310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity.
    Hinkula J
    Expert Rev Vaccines; 2007 Apr; 6(2):203-12. PubMed ID: 17408370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
    J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates.
    Bertley FM; Kozlowski PA; Wang SW; Chappelle J; Patel J; Sonuyi O; Mazzara G; Montefiori D; Carville A; Mansfield KG; Aldovini A
    J Immunol; 2004 Mar; 172(6):3745-57. PubMed ID: 15004179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of mucosal immunity in prevention of HIV transmission.
    Kozlowski PA; Neutra MR
    Curr Mol Med; 2003 May; 3(3):217-28. PubMed ID: 12699359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.
    Buonaguro L; Devito C; Tornesello ML; Schröder U; Wahren B; Hinkula J; Buonaguro FM
    Vaccine; 2007 Aug; 25(32):5968-77. PubMed ID: 17629365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel vaccination protocol with two live mucosal vectors elicits strong cell-mediated immunity in the vagina and protects against vaginal virus challenge.
    Li Z; Zhang M; Zhou C; Zhao X; Iijima N; Frankel FR
    J Immunol; 2008 Feb; 180(4):2504-13. PubMed ID: 18250460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge.
    Dumais N; Patrick A; Moss RB; Davis HL; Rosenthal KL
    J Infect Dis; 2002 Oct; 186(8):1098-105. PubMed ID: 12355360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.
    Kent SJ; Dale CJ; Ranasinghe C; Stratov I; De Rose R; Chea S; Montefiori DC; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Law M; Wilson KM; Ramsay AJ
    Vaccine; 2005 Oct; 23(42):5009-21. PubMed ID: 15985317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective mucosal immunity elicited by targeted lymph node immunization with a subunit SIV envelope and core vaccine in macaques.
    Lehner T; Wang Y; Cranage M; Bergmeier LA; Mitchell E; Tao L; Hall G; Dennis M; Cook N; Jones I; Doyle C
    Dev Biol Stand; 1998; 92():225-35. PubMed ID: 9554279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mucosal immunization with DNA-liposome complexes.
    Klavinskis LS; Gao L; Barnfield C; Lehner T; Parker S
    Vaccine; 1997 Jun; 15(8):818-20. PubMed ID: 9234523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A rational basis for mucosal vaccination against HIV infection.
    Lehner T; Bergmeier L; Wang Y; Tao L; Mitchell E
    Immunol Rev; 1999 Aug; 170():183-96. PubMed ID: 10566151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The immunologic aspects of human immunodeficiency virus infection in the gastrointestinal tract.
    Schneider T; Ullrich R; Zeitz M
    Semin Gastrointest Dis; 1996 Jan; 7(1):19-29. PubMed ID: 8903576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies.
    Chege GK; Burgers WA; Müller TL; Gray CM; Shephard EG; Barnett SW; Ferrari G; Montefiori D; Williamson C; Williamson AL
    Vaccine; 2017 Feb; 35(6):929-937. PubMed ID: 28069361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site.
    Wang B; Dang K; Agadjanyan MG; Srikantan V; Li F; Ugen KE; Boyer J; Merva M; Williams WV; Weiner DB
    Vaccine; 1997 Jun; 15(8):821-5. PubMed ID: 9234524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravaginal immunisation using a novel antigen-releasing ring device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses.
    McKay PF; Mann JF; Pattani A; Kett V; Aldon Y; King D; Malcolm RK; Shattock RJ
    J Control Release; 2017 Mar; 249():74-83. PubMed ID: 28115243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal delivery of vaccines against HIV.
    Vajdy M; Singh M
    Expert Opin Drug Deliv; 2006 Mar; 3(2):247-59. PubMed ID: 16506951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy.
    Jackson RJ; Worley M; Trivedi S; Ranasinghe C
    Vaccine; 2014 Sep; 32(43):5703-14. PubMed ID: 25151041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.